FDA Again Denies Merck’s Request for OTC “Mevacor” - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Again Denies Merck’s Request for OTC “Mevacor”


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Whitehouse Station, NJ (Jan. 25)—The US Food and Drug Administration has issued a not approvable letter to Merck & Co. in regards to their request for over-the-counter (OTC) use of “Mevacor” (lovastatin) 20 mg. FDA’s letter indicates a revised label would be required as well as additional data from Merck.

This decision follows the FDA’s Nonprescription Drugs Advisory and Endocrinologic and Metabolic Drugs Advisory committees’ recommended rejection in December of 2007. Edwin L. Hemwall, PhD, Merck’s Vice President of Global OTC Regulatory and Scientific Affairs, said the company is “evaluating the conditions outlined in the agency’s response to determine a path forward for ‘Mevacor’ OCT.”

Under review by FDA since 1999, not approvable letters were also issued in 2000 and 2005. “Mevacor” is designed to reduce LDL cholesterol levels in patients.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here